• α-Bungarotoxin for Nicotinic Receptor Blockade

  2026-08-30

  Use α-Bungarotoxin to test whether α7 nicotinic acetylcholine receptor signaling is required for a cellular or tissue response, rather than merely correlated with it. This practical guide connects receptor pharmacology with neuronal, neuromuscular, neurotoxicity, and placental necroptosis workflows while emphasizing controls, dosing pilots, and interpretation limits.

• Cy5-UTP for Spatial RNA Trafficking Assays

  2026-08-29

  Cy5-UTP enables direct fluorescent RNA probe synthesis for mapping transcript localization and trafficking. This article connects Cyanine 5-uridine triphosphate chemistry with a recent mechanistic study of axonal RNP transport, while defining practical controls and interpretation limits.

• E-64d: Designing Better Cell-Death Assays

  2026-08-28

  Explore how E-64d can clarify intracellular cysteine protease biology while MEDUSA-inspired, time-resolved assays separate cell growth from true death. Includes mechanism, applications, controls, and handling guidance.

• IBDV VP3 Reprograms IRF7 Proteasome Turnover

  2026-08-28

  Wang et al. identify IBDV VP3 as a viral factor that suppresses IRF7-dependent type I interferon signaling by promoting proteasome-associated IRF7 degradation. The study connects this immune-evasion mechanism to enhanced viral replication and provides a framework for testing how ubiquitin-dependent protein turnover shapes antiviral responses.

• SU 5402 in Human Neuron Signaling Assays

  2026-08-27

  SU 5402 offers a powerful way to interrogate receptor tyrosine kinase signaling alongside human iPSC-derived sensory neuron models. This guide explains how to separate pathway effects from cytotoxicity when studying HSV-1 latency, reactivation, cancer biology, and apoptosis.

• Pam3CSK4 in Translational Neuro-Immune Research

  2026-08-27

  Pam3CSK4 offers a defined TLR1/2 agonist platform for connecting innate immune signaling with airway inflammation and emerging neuro-immune biology. This thought-leadership guide explains how to position the reagent in mechanistic workflows, interpret immune phenotypes, and build translationally relevant validation strategies without overextending the evidence.

• TLS, CD40–STING Competition in ESCC

  2026-08-26

  A 2025 study identifies tertiary lymphoid structures as favorable prognostic features in treatment-naïve esophageal squamous cell carcinoma and links them to activated, IRF4-positive B cells. Integrated transcriptomic, single-cell, and in vitro analyses support a mechanism in which CD40 and STING compete for TRAF2, shaping non-canonical NF-κB activity, STING modification, and B-cell activation.

• Disulfiram Workflows for Proteasome and Pyroptosis

  2026-08-26

  Disulfiram is a practical research tool for connecting copper-sensitive proteasome inhibition with apoptotic cancer cell death induction. This workflow shows how to use it in purified-enzyme assays, breast cancer MDA-MB-231 cell line research, and carefully controlled pyroptosis experiments without conflating Disulfiram data with the distinct NU6300 mechanism.

• NU6300 Targets Gasdermin D at Cys-191

  2026-08-25

  Jiang et al. identify NU6300 as a covalent gasdermin D inhibitor that targets cysteine-191 and blocks both cleavage and palmitoylation. The study connects this molecular mechanism to reduced pyroptosis, protection in experimental colitis, and improved survival in endotoxemia, while clarifying pathway-specific effects across inflammasomes.

• 3-Deazaneplanocin (DZNep): Assay Strategy

  2026-08-25

  3-Deazaneplanocin (DZNep) is an epigenetic modulator that connects SAHH inhibition with EZH2-dependent chromatin remodeling. This guide focuses on experimental design, orthogonal validation, and context-aware interpretation across AML, hepatocellular carcinoma, and metabolic disease models.

• In Vitro Drug Response Metrics in Cancer Research

  2026-08-24

  Hannah Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but non-equivalent dimensions of anti-cancer drug response. This framework supports better endpoint selection, time-course design, and interpretation of cytotoxicity experiments.

• MLN2238 Proteasome β5 Inhibition Workflows

  2026-08-24

  Build cleaner proteasome-target engagement, apoptosis, and proteotoxic-stress assays with MLN2238, a reversible inhibitor that favors the β5 site. Its concentration-dependent subunit profile also supports controlled comparisons in multiple myeloma, lymphoma, and bortezomib-resistant cell models.

• 2,7-Dichlorodihydrofluorescein diacetate: ROS Workflows

  2026-08-23

  Build more informative oxidative-stress experiments with DCFH-DA across imaging, flow cytometry, and plate-based screening. This guide connects intracellular ROS readouts with organellar DNA-damage research while emphasizing controls, assay boundaries, and practical troubleshooting.

• Fluoxetine HCl Workflows for Motivation Research

  2026-08-22

  Fluoxetine HCl supports controlled studies of serotonin transport, 5-HT2C signaling, and reward-related phenotypes from membrane assays to animal behavior. This workflow separates acute serotonergic pharmacology from developmental SSRI effects, helping researchers interpret motivation, neurogenesis, and synaptic plasticity results more rigorously.

• Melatonin, RIPK3, and Atrazine-Induced Kidney Injury

  2026-08-22

  The reference study identifies RIPK3-dependent necroptosis as a central mechanism of atrazine-induced renal injury and shows that melatonin suppresses this pathway across in vivo and in vitro models. Its combination of pathway analysis, RIPK3 knockdown, and computational modeling provides a useful framework for distinguishing antioxidant protection from direct regulation of necroptotic signaling.

8535 records 1/569 page Next 12345 下5页 Last page